"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 1 | 4 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 4 | 7 |
| 2003 | 0 | 3 | 3 |
| 2004 | 3 | 4 | 7 |
| 2005 | 3 | 2 | 5 |
| 2006 | 1 | 0 | 1 |
| 2007 | 8 | 4 | 12 |
| 2008 | 6 | 2 | 8 |
| 2009 | 3 | 3 | 6 |
| 2010 | 2 | 8 | 10 |
| 2011 | 7 | 1 | 8 |
| 2012 | 8 | 7 | 15 |
| 2013 | 9 | 8 | 17 |
| 2014 | 6 | 2 | 8 |
| 2015 | 9 | 4 | 13 |
| 2016 | 6 | 4 | 10 |
| 2017 | 11 | 6 | 17 |
| 2018 | 11 | 5 | 16 |
| 2019 | 5 | 3 | 8 |
| 2020 | 10 | 3 | 13 |
| 2021 | 11 | 2 | 13 |
| 2022 | 6 | 1 | 7 |
| 2023 | 8 | 1 | 9 |
| 2024 | 9 | 7 | 16 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):123-130.
-
Increasing Access to Antiretroviral Therapy for the Prevention and Treatment of HIV in Infants, Children, and Youth in the United States: Policy Statement. Pediatrics. 2025 Aug 01; 156(2).
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
HIV Preexposure Prophylaxis Service Delivery Models for Emergency Departments: A Qualitative Study. J Int Assoc Provid AIDS Care. 2025 Jan-Dec; 24:23259582251342842.
-
Low-level viraemia as a risk factor for virologic failure in children and adolescents living with HIV on antiretroviral therapy in Tanzania: a multicentre, retrospective cohort study. J Int AIDS Soc. 2025 May; 28(5):e26474.
-
Attitudes and Barriers Toward Antiretroviral Therapeutic Drug Monitoring Among Infectious Disease Providers. Medicina (Kaunas). 2025 Mar 20; 61(3).
-
The Leaky Preexposure Prophylaxis Cascade-Barriers and Facilitators to Preexposure Prophylaxis Uptake and Adherence Among Youth Experiencing Homelessness in the US South: A Mixed Methods Study. J Assoc Nurses AIDS Care. 2025 May-Jun 01; 36(3):271-283.
-
Viral load suppression and retention in care among children and adolescents receiving multi-month anti-retroviral therapy refills: a program data review in Uganda. BMC Pediatr. 2024 Dec 07; 24(1):804.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.
-
Birth outcomes following bictegravir exposure during pregnancy. AIDS. 2025 Mar 15; 39(4):381-386.